STOK Quote, Financials, Valuation and Earnings

Biogen, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of 19%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Biogen, Inc.'s return on equity of 9.36%.

Stoke Therapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 2.15%. On the other hand Biogen, Inc. has an analysts' consensus of $178.76 which suggests that it could fall by -1.77%. Given that Stoke Therapeutics, Inc. has higher upside potential than Biogen, Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Biogen, Inc..

Stoke Therapeutics, Inc. has a beta of 1.138, which suggesting that the stock is 13.807% more volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.128, suggesting its less volatile than the S&P 500 by 87.226%.

Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.

Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Stoke Therapeutics, Inc.'s net income of -$38.3M is lower than Biogen, Inc.'s net income of $466.5M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 46.92x while Biogen, Inc.'s PE ratio is 16.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 8.78x versus 2.75x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of -259.95%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Insmed, Inc.'s return on equity of -193.23%.

Stoke Therapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 2.15%. On the other hand Insmed, Inc. has an analysts' consensus of $220.41 which suggests that it could grow by 6.59%. Given that Insmed, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Insmed, Inc. is more attractive than Stoke Therapeutics, Inc..

Stoke Therapeutics, Inc. has a beta of 1.138, which suggesting that the stock is 13.807% more volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.

Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Stoke Therapeutics, Inc.'s net income of -$38.3M is higher than Insmed, Inc.'s net income of -$370M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 46.92x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 8.78x versus 88.00x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Janux Therapeutics, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of -243.13%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Janux Therapeutics, Inc.'s return on equity of -10.94%.

Stoke Therapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 2.15%. On the other hand Janux Therapeutics, Inc. has an analysts' consensus of $68.59 which suggests that it could grow by 300.87%. Given that Janux Therapeutics, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Stoke Therapeutics, Inc..

Stoke Therapeutics, Inc. has a beta of 1.138, which suggesting that the stock is 13.807% more volatile than S&P 500. In comparison Janux Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Janux Therapeutics, Inc. pays out -- of its earnings as a dividend.

Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are larger than Janux Therapeutics, Inc. quarterly revenues of $10M. Stoke Therapeutics, Inc.'s net income of -$38.3M is lower than Janux Therapeutics, Inc.'s net income of -$24.3M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 46.92x while Janux Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 8.78x versus 103.75x for Janux Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of -45.06%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.

Stoke Therapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 2.15%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $19.91 which suggests that it could fall by -8.84%. Given that Stoke Therapeutics, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Sarepta Therapeutics, Inc..

Stoke Therapeutics, Inc. has a beta of 1.138, which suggesting that the stock is 13.807% more volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.537, suggesting its less volatile than the S&P 500 by 46.348%.

Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Stoke Therapeutics, Inc.'s net income of -$38.3M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 46.92x while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 8.78x versus 0.93x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.